Search results for "lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens"

showing 10 items of 382 documents

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

2020

Background: Radiology-based outcomes, such as progression-free survival (PFS) and objective response rate (ORR), are used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of PFS with overall survival (OS) in clinical trials of systemic therapies targeting advanced hepatocellular carcinoma (HCC) by novel meta-regression methods. Methods: A search of databases (PubMed, American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) Meeting Libraries, Clinicaltrials.gov) for trials of systemic therapies for advanced HCC reporting both OS and PFS was performed. Individual patient data were extracted from PFS and OS Kaplan&nd…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentoverall survivallcsh:RC254-282ArticleSettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpointmedicineOverall survival030212 general & internal medicineProgression-free survivalneoplasmsSettore MED/12 - Gastroenterologiabusiness.industrySurrogate endpointImmunotherapyhepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialOncologyQuartile030220 oncology & carcinogenesisHepatocellular carcinomasurrogate endpointsimmunotherapySettore SECS-S/01 - Statisticabusinessprogression-free survivalCancers
researchProduct

Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

2020

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregiona…

OncologyCancer Researchmedicine.medical_specialtyuterine sarcomamedicine.medical_treatmentchemotherapylcsh:RC254-282meta-analysiArticleNOuterine leiomyosarcoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapy030212 general & internal medicineStage (cooking)meta-analysis uterine leiomyosarcoma uterine sarcoma adjuvant therapy chemotherapyUterine sarcomabusiness.industryadjuvant therapyOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialRadiation therapymeta-analysisadjuvant therapy chemotherapyOncology030220 oncology & carcinogenesisMeta-analysisAdjuvant therapy Uterine sarcoma Uterine leiomyosarcoma Meta-analysis ChemotherapybusinessCancers
researchProduct

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

2019

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the …

OncologyEribulin Mesylatemedicine.medical_specialtymulticentreThird-line therapylcsh:RC254-282chemistry.chemical_compoundInternal medicinemedicineIn patienteribulin metastatic breast cancer multicentre prospective real world third lineeribulinthird lineOriginal Researchbusiness.industryreal worldprospectivemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMetastatic breast cancerSafety profileSurvival benefitOncologychemistryObservational studymetastatic breast cancerbusinessEribulinTherapeutic Advances in Medical Oncology
researchProduct

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensu…

2012

Abstract Background Recent emerging evidences identify Human Papillomavirus (HPV) related Head and Neck squamous cell carcinomas (HN-SCCs) as a separate subgroup among Head and Neck Cancers with different epidemiology, histopathological characteristics, therapeutic response to chemo-radiation treatment and clinical outcome. However, there is not a worldwide consensus on the methods to be used in clinical practice. The endpoint of this study was to demonstrate the reliability of a triple method which combines evaluation of: 1. p16 protein expression by immunohistochemistry (p16-IHC); 2. HPV-DNA genotyping by consensus HPV-DNA PCR methods (Consensus PCR); and 3 viral integration into the host…

OncologyHuman papillomavirusHPVCancer Researchmedicine.medical_specialtyPathologyMethylation-Specific PCREpidemiologySettore MED/50 - Scienze Tecniche Mediche ApplicateBisulfite sequencingConsensus PCRIn situ hybridizationSettore MED/08 - Anatomia Patologicalcsh:RC254-282lcsh:Infectious and parasitic diseasesHPV-DNA; in situ hybridationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineDNA consensus PCRlcsh:RC109-216p16-IHCin situ hybridationGenotypingHN-SCCOPSCCbusiness.industryHead and neck cancerEpigeneticHPV-DNAHead and neck squamous cell carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryHead and neck squamous-cell carcinomastomatognathic diseasesInfectious DiseasesReal-time polymerase chain reactionOncologyImmunohistochemistryOSCCbusinessResearch ArticleIHCInfectious Agents and Cancer
researchProduct

P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study

2005

Abstract Background P-cadherin (P-cad) is a transmembrane molecule involved in the cell-cell adhesion and similar to E-cadherin (E-cad), but less investigated in oncology, especially in in vivo studies. Aims of the present study were to assess the prevalence of P-cad expression in oral squamous cell carcinoma (OSCC) and to verify whether P-cad can be considered a marker of prognosis in patients with OSCC. Methods In a retrospective study, a cohort of 67 OSCC patients was investigated for P-cad expression and its cellular localization by immunohistochemistry; some respective healthy margins of resection were similarly investigated as standard controls. After grouping for P-cad expression, OS…

OncologyMalePathologyCancer ResearchCytoplasmTime FactorsCohort StudiesSurgical oncologyCellular localizationMouth neoplasmAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCadherinsPrognosisImmunohistochemistryTreatment OutcomeOncologycell-cell adhesionCarcinoma Squamous CellImmunohistochemistryRegression AnalysisFemaleMouth NeoplasmsResearch ArticleAdultmedicine.medical_specialtyAdolescentlcsh:RC254-282Internal medicinemedicineGeneticsBiomarkers TumorHumanscardiovascular diseasesGrading (tumors)Survival rateAgedProportional Hazards ModelsRetrospective StudiesModels StatisticalProportional hazards modelCadherinbusiness.industryCell MembraneCateninstomatognathic diseasesMultivariate AnalysisCadherinbusinessCell Adhesion Molecules
researchProduct

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

2020

The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative p…

OncologyOpinionmedicine.medical_specialty2019-20 coronavirus outbreakCancer ResearchtherapyCoronavirus disease 2019 (COVID-19)business.industrySettore MED/06 - Oncologia MedicaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)screeningCancerCOVID-19medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncologyCOVID-19 cancer prognosis screening therapyInternal medicinemedicinecancerprognosisbusinessFrontiers in Oncology
researchProduct

Epulis-Like Presentation of Gingival Renal Cancer Metastasis

2017

Mouth metastatic cancers are very rare and they usually represent the evidence of a widespread disease. Common primary tumors are lung carcinoma in men and breast carcinoma in women, followed by kidney cancer. In the oral soft tissues, the gingiva is the most common site, suggesting a possible role of inflammation in the attraction of circulating tumor cells. Oral metastasis has a serious prognosis. In this work, we describe the case of a 58-year-old man affected by renal cancer, who was brought to our attention for the appearance of a gingival swelling. Initially, the lesion was excised through a provisional clinical diagnosis of epulis. Subsequently, anatomopathological analysis showed a …

OncologyPathologymedicine.medical_specialtyEpulisOphtalmologieCase Reportlcsh:RC254-282MetastasisMetastasis03 medical and health sciences0302 clinical medicineCirculating tumor cellClear-cell adenocarcinomaInternal medicineCarcinomamedicineClear-cell adenocarcinomaRiñones -- CáncerCell proliferationbusiness.industryOral cancerCancerMetástasisKidney cancer030206 dentistryCáncerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBoca -- CáncerOncology030220 oncology & carcinogenesisbusinessBreast carcinomaKidney cancer
researchProduct

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

2009

Abstract Background The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown. Methods We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis. Resu…

Oncologymedicine.medical_specialtyCancer ResearchBreast Neoplasmsmedicine.disease_causelcsh:RC254-282Disease-Free SurvivalWhite PeopleBreast cancerInternal medicineGeneticsMedicineHumansAlleleAllelesPolymorphism Geneticbusiness.industryHaplotypeCancerOdds ratioMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInterleukin 1 Receptor Antagonist ProteinIL1AOncologyImmunologyFemaleGene polymorphismbusinessCarcinogenesisInterleukin-1Research ArticleBMC Cancer
researchProduct